Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | PTAFR | P25105 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410599 | 0.78 | LMNA (0.50) | LMNAKMT2ATDP1CHRNA7ALDH1A1 | |
| SCHEMBL28134030 | 0.76 | TBXAS1 (0.58) | LMNAKMT2ATDP1CHRNA7KDM4E | |
| SCHEMBL29883579 | 0.74 | CYP19A1 (0.47) | LMNAKMT2ATDP1ALDH1A1TBXAS1 | |
| SCHEMBL5405873 | 0.74 | LTA4H (0.51) | KMT2AKDM4EALDH1A1HCAR2 | |
| SCHEMBL5405877 | 0.74 | LTA4H (0.51) | KMT2AKDM4EALDH1A1HCAR2 | |
| SCHEMBL304802 | 0.73 | TDP1 (0.60) | LMNAKMT2ATDP1CHRNA7KDM4E | |
| SCHEMBL5414119 | 0.73 | LTA4H (0.50) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL5414125 | 0.73 | LTA4H (0.50) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL4076761 | 0.72 | KMT2A (0.58) | LMNAKMT2ATDP1CHRNA7KDM4E | |
| SCHEMBL26698327 | 0.72 | CHRNA7 (0.53) | LMNACHRNA7TBXAS1NAPRTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247645-B2 | Dihydropyridine derivatives | AJINOMOTO CO., INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20020147222-A1 | Dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-10-10 | — | — | US | disclosed |
| EP-1191021-A1 | DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147222-A1 | Dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | LMNA 1847/4885KMT2A 4223/4885TDP1 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.